Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma 2024-08-27 17:00
Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress 2024-05-30 18:10
JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma 2024-01-04 21:40
JW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy 2024-01-02 20:15
JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus 2023-04-10 19:30
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients 2023-03-30 08:00
JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma 2023-03-08 17:30
JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma 2023-02-28 17:30
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting 2022-12-12 18:00
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients 2022-11-09 17:00
JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies 2022-10-27 07:53
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma 2022-10-10 20:00
JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma 2022-07-04 19:30
JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting 2022-06-05 18:30
JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting 2022-05-09 09:00
JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting 2022-05-09 09:00
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 200 Chinese Patients 2022-04-25 15:08
JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric and Young Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia 2022-04-20 18:30
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China 2022-04-03 18:05
JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma 2022-03-31 12:20
1 2